跳至主要内容
临床试验/NCT04527276
NCT04527276已完成不适用

Reducing the Incidence of Ventilator Associated Pneumonia in Critically Ill Children: a Randomized Controlled Trial to Assess the Efficacy of Oral Mucosal Mouthwashes With Chlorhexidine

Istanbul Medeniyet University1 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2019年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
138
试验地点
1
主要终点
Prevalance of VAP

研究概览

简要总结

This was a single-centered, randomized, placebo-controlled double-blind clinical trial conducted in the pediatric intensive care unit (PICU), in patients who were aged 1 month to 18 years, needing MV for at least 48 hours, to evaluate the effect of Chlorhexidine (CHX) on Ventilator-associated pneumonia (VAP) incidence and to determine VAP risk factors.

详细描述

Patients were randomized into two groups receiving CHX (0.12%) or placebo (0.9% NaCl) and followed for VAP development. All patients were consecutively randomized (1:1) to receive either 0.12% CHX rinse solution or placebo applications using a computer generated balanced randomization table. The unlabeled standardized tubes containing placebo or 0.12% CHX were serially numbered and bagged for each patient according to randomization. The preparation of bagged treatments and their numbering were done by the same personnel who was not involved in the study. The placebo rinse contained 0.9% NaCl (normal saline [NS]), and was identical to the 0.12% CHX rinse solution with regard to appearance, consistency, taste and smell. The patients, physicians, outcome assessors, and data analysts were kept blinded to the intervention.

The standard care protocols in the PICU were performed. Before beginning the study, nurses received a training program for VAP prevention, procedure/technique for oral hygiene and use of oral mucosa assessment score under supervision of pediatric residents. They were trained on the method of application of solutions according to CDC guidelines in order to ensure uniform treatments. Nurses were double blinded and had no knowledge of the solution they were using.

Both treatment groups (placebo and 0.12% CHX) received treatments at 4-hour intervals, nurses used the whole content of 5 ml tubes containing rinse solution. In both groups, nurses performed oral cleansing as follows: first, the endotracheal cuff pressure was tested to ensure proper pressure prior to oral care and oropharyngeal secretions were aspirated to remove any accumulated secretions. Then the application of rinse solutions to cleanse all areas of the oral cavity, including the anterior and posterior pharynx, gums, teeth, tongue, and buccal mucosa, with standard disposable applicator (foam swab) was applied, followed by removal of excess solution from the mouth by a sterile catheter. Strict hand hygiene was ensured during the procedures. The period of application was from the day of intubation until extubation. Presence of any adverse effect of the solutions was recorded. Beck oral assessment score (BOAS) was used twice daily to evaluate the oral health of both groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
1 Month 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • aged 1 month to 18 years
  • needing MV for at least 48 hours
  • PICU patients

排除标准

  • not consenting to participate in the study
  • known hypersensitivity to CHX
  • presence of tracheotomy,
  • undergoing MV for less than 48 hours
  • having received MV for more than 24 hours prior to PICU admission
  • readmission to PICU
  • suspected or diagnosed immunodeficiency
  • history of malignant disease(active or at remission),
  • being diagnosed with oral mucositis or periodontal disease
  • chronic pulmonary and/or cardiac diseases
  • having severe oral/facial trauma,
  • use of immunosuppressive drugs (such as corticosteroids).

结局指标

主要结局

Prevalance of VAP

时间窗: 14 days

Prevalance of VAP /1000 ventilator days (actual number of VAP episodes)

Characteristics of VAP

时间窗: 14 days

Early onset vs. late onset VAP rate

次要结局

  • Causative organism(14 days)
  • Causative organisms of VAP(14 days)
  • Duration of PICU stay(12 months)
  • Duration of Hospital stay(12 months)
  • Duration of ventilation(12 months)
  • Survival(12 months)
  • Causative organism of VAP(14 days)

研究者

发起方
Istanbul Medeniyet University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zeynep Karakaya

Principal investigator

Istanbul Medeniyet University

研究点 (1)

Loading locations...

相似试验